Bertaux J F
Soz Praventivmed. 1980 Mar;25(1-2):23-5. doi: 10.1007/BF02075065.
The competence of the World Health Organization in the area of safety of pharmaceutical products is based on its constitution and on several resolutions of the World Health Assembly. Evaluation of the safety of pharmaceutical products is one of the major concerns of WHO together with other research activities in the socioeconomic field. The following programmes, amongst others, make up this activity: international drug monitoring, exchange of information on decisions of withdrawal or changes in drug use and on marketing of new products, commented information on problems of international interest, exchange of information on registration systems and control of drug marketing in different countries. Several systems of communication exist between WHO and Member States, but of these the Drug Information Bulletin is the most important. In the future, WHO may provide an independent forum for the discussion of topics relating to drug safety which are of interest to the International community.
世界卫生组织在药品安全领域的权限基于其章程以及世界卫生大会的若干决议。药品安全评估是世卫组织的主要关切之一，与社会经济领域的其他研究活动一样重要。以下方案等构成了这一活动：国际药品监测、关于药品撤市或用药变更及新产品上市决定的信息交流、有关具有国际意义问题的评论性信息、关于注册系统的信息交流以及不同国家药品市场监管。世卫组织与成员国之间存在多种沟通系统，其中《药品信息通报》最为重要。未来，世卫组织可能会提供一个独立论坛，用于讨论国际社会感兴趣的与药品安全相关的议题。
